文献速递银屑病与炎症性皮肤病

Certolizumab pegol治疗慢性斑块状银屑病:两项3期、多中心、随机、双盲、安慰剂对照研究(CIMPASI-1和CIMPASI-2)的48周结果

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2).
PubMed 文献 · J Am Acad Dermatol · 2018-04-13

两项3期随机双盲安慰剂对照研究评估Certolizumab pegol治疗中重度慢性斑块状银屑病的疗效与安全性,患者按2:2:1随机接受400 mg、200 mg或安慰剂每2周一次。第16周两种剂量疗效均显著优于安慰剂,并维持至第48周,400 mg在多数指标上数值更优,安全性符合该治疗类别。

要点

  • 第16周两种剂量疗效均显著优于安慰剂,并维持至第48周。
  • 多数指标上400 mg改善数值更优,可能提供额外临床获益。
  • 未发现非预期安全信号,安全性符合治疗类别。

核心结论

  • 每2周一次Certolizumab pegol 400 mg或200 mg治疗均可显著改善中重度银屑病,400 mg可能提供额外临床获益。

研究设计与样本

  • 两项3期、多中心、随机、双盲、安慰剂对照研究,中重度慢性斑块状银屑病患者按2:2:1随机接受Certolizumab pegol 400 mg、200 mg或安慰剂每2周一次。

主要发现

  • 第16周两种剂量疗效均显著优于安慰剂,并维持至第48周。
  • 多数指标上400 mg改善数值更优。
  • 未发现非预期安全信号。

关键数值与推荐

  • 共同主要终点为第16周应答率:银屑病面积与严重程度指数降低75%,以及医生总体评估0/1(清除/几乎清除)且改善≥2分。

临床怎么用

  • 原文未报告临床推荐。

局限性

  • 无活性对照药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Certolizumab pegol, the only Fc-free, PEGylated anti-tumor necrosis factor biologic, demonstrated clinically meaningful improvements suggestive of a positive risk-benefit balance in phase 2 studies in adults with moderate-to-severe chronic plaque psoriasis. OBJECTIVE: Assess certolizumab efficacy and safety versus placebo in phase 3 studies. METHODS: Patients with moderate-to-severe chronic plaque psoriasis were randomized 2:2:1 to certolizumab 400 mg, certolizumab 200 mg, or placebo every 2 weeks. At week 16, certolizumab-treated patients achieving a 50% reduction in Psoriasis Area and Severity Index continued treatment through week 48. Coprimary endpoints were week 16 responder rates, defined as a 75% reduction in Psoriasis Area and Severity Index and Physician's Global Assessment 0/1 (clear/almost clear) and ≥2-point improvement. Safety was assessed by treatment-emergent adverse events. RESULTS: Week-16 endpoints were significantly greater for both doses of certolizumab versus placebo, and the responses were maintained through week 48. For most measures, improvement was numerically greater for certolizumab 400 mg. No unexpected safety signals were identified. LIMITATION: There was no active comparator. CONCLUSION: Treatment with either certolizumab 400 mg or 200 mg every 2 weeks was associated with significant and clinically meaningful improvements in moderate-to-severe psoriasis. The 400-mg dose could provide additional clinical benefit. The safety profile was consistent with the therapeutic class.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Gottlieb AB, Blauvelt A, Thaçi D, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). J Am Acad Dermatol. 2018. PMID: 29660421. doi:10.1016/j.jaad.2018.04.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。